Naslov
Antitrust issues in the European pharmaceutical market – the latest developments

Autori
Pošćić, Ana

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Skup
17. Simpozij “Comprehensive Approach to Personalized Medicine – Medical, Legal and Economic Implications for Croatian Healthcare System”

Mjesto i datum
Opatija, Hrvatska; Rijeka, Hrvatska, 10.11.2016. - 11.11.2016

Vrsta sudjelovanja
Predavanje

Vrsta recenzije
Nije recenziran

Ključne riječi
Antitrust Issues, European Pharmaceutical Market, intellectual property

Sažetak
The presentation will discuss the major EU competition law developments in the pharmaceutical sector. Decisions in Lundbeck, Servier and J&J/Novartis provide a guidance on how the European Commission approaches intellectual property and regulatory issues that delay generic entry. Special attention is on the novel concept of “abusive denigration“, of which there is no mention in the Treaty on the functioning of the European Union and no decisions by the European Commission. After a brief discussion of intellectual property rights in pharmaceuticals, EU competition rules and practices, in particular pricing strategies of innovative pharmaceutical companies and their impact on competition, emphasis will be on the legality of national measures that limit parallel trade. It will be shown that the Court of Justice of the EU has adopted a compromise whereby pharmaceutical companies may not block all parallel trade but may take reasonable and appropriate measures in order to protect their legitimate commercial interests.

Izvorni jezik
Engleski

Znanstvena područja
Pravo

POVEZANOST RADA